Quoin Pharmaceuticals Ltd. — $50M Form D filing, September 2026

What the filing says

• Offered: $50,000,649. Sold: $50,000,649. Left to sell: nothing, all of it is sold. (filing)
• Investors: 33 had already invested. (filing)
• Date of first sale: August 31, 2026. (filing)
• Types of securities: Equity; Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right. (filing)
• Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. It adds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.” (filing)
• On the amounts offered and sold: the filing adds “The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.” (filing)
• On sales commissions and finders' fees: the filing adds “Consists of fees due to placement agents equal in aggregate to 6.0% of gross offering proceeds, assuming cash exercise of all warrants issued. Lead placement agent also entitled to reimbursement for reasonable out-of-pocket expenses, not included here.” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Quoin Pharmaceuticals Ltd. See pricing